Avalo Therapeutics Inc. said its chief financial officer, Christopher Ryan Sullivan, sold more than 72,000 shares worth approximately $1.45 million under a pre-arranged trading plan adopted in May 2026.
The transactions occurred on Aug. 17 and Aug. 18, with an additional sale on Aug. 31, all executed under the Rule 10b5-1 plan. On Aug. 17, Sullivan sold 37,945 shares for $753,333 at prices between $19.16 and $20.02 per share, and an additional 3,749 shares at $19.70 to $20.02. The following day, he sold 31,031 shares at $20.00 to $20.265 per share. Combined, those sales totaled $697,085.
Sullivan also exercised stock options to acquire 71,852 shares at $9.88 per share, with a combined acquisition cost of $709,897. The options vest 25% on March 28, 2025, with the remainder vesting monthly over the following three years, subject to continued employment.
Avalo’s shares closed at $19.74 on Friday, up 110% over the past year and giving the company a market capitalization of about $1.03 billion. Analysts at Leerink initiated coverage with an Outperform rating and a $38 price target, citing positive Phase 2 data for the company’s lead asset, abdakibart, in hidradenitis suppurativa. Cantor Fitzgerald maintained an Overweight rating, noting potential implications from AbbVie’s Phase 3 readout for lutikizumab expected in 2026.
The biopharmaceutical company was added to the Russell 2000 and 3000 indexes earlier this year. Avalo also appointed Ron Philip to its board, tapping his over three decades of biopharmaceutical experience for roles on the Compensation Committee and the Science, Development and Commercial Advisory Committee.
